Markets:

Overview

News

Currencies

International

Treasuries

Curis, Inc. - Common Stock (NQ:CRIS)

0.9955 +0.0456 (+4.80%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Curis, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Curis Inc. (NASDAQ: CRIS) Leading the Way in Friday Trading Based on Percentage Gain

November 17, 2023

Via Investor Brand Network

Preview: Curis's Earnings ↗

November 01, 2023

Via Benzinga

Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday ↗

September 29, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares...

Via Benzinga

Topics Stocks

Analyst Ratings for Curis ↗

September 25, 2023

Via Benzinga

Expert Ratings for Curis ↗

September 07, 2023

Via Benzinga

Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study ↗

July 07, 2023

Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib

Via Benzinga

Why Curis (CRIS) Shares Are Nosediving Thursday ↗

July 06, 2023

Curis, Inc. (NASDAQ: CRIS) shares are trading lower by 8.29% to $0.75 Thursday morning after the company announced a $15.1 million registered direct offering.

Via Benzinga

Curis's Return On Capital Employed Overview ↗

March 15, 2023

Via Benzinga

A Preview Of Curis's Earnings ↗

March 10, 2023

Via Benzinga

Earnings Preview For Curis ↗

March 08, 2023

Via Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

Meta Platforms To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Friday ↗

July 07, 2023

Needham raised the price target for Applied Digital Corporation (NASDAQ: APLD) from $8.5 to $16. Needham analyst John Todaro maintained a Buy rating. Applied Digital shares fell 14.2% to close at $7.70...

Via Benzinga

Looking Into Curis's Return On Capital Employed ↗

December 15, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 06, 2023

Via Benzinga

Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗

March 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 12, 2022

Via Benzinga

Earnings Outlook For Curis ↗

November 08, 2022

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an...

Via Benzinga

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗

December 13, 2022

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

Via Benzinga

Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket ↗

September 26, 2022

Gainers

Via Benzinga

Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

December 12, 2022

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 30, 2022

Via Benzinga

Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold ↗

August 30, 2022

The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.

Via Benzinga

Curis's Return On Capital Employed Insights ↗

August 24, 2022

According to Benzinga Pro data, during Q2, Curis (NASDAQ:CRIS) posted sales of $2.39 million. Earnings were up 1.05%, but Curis still reported an overall loss of $15.94 million.

Via Benzinga

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗

August 19, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Analyzing Curis Short Interest ↗

August 18, 2022

Curis (NASDAQ:CRIS) short percent of float has fallen 4.29% since its last report. The company recently reported that it has 3.58 million shares sold short, which is...

Via Benzinga

Dow Falls 60 Points; Crude Oil Rises Sharply ↗

August 18, 2022

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 60 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 18, 2022

Via Benzinga

BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy ↗

August 18, 2022

Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children.

Via InvestorPlace

Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

August 18, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.